Safety and Efficacy of High-Dose OnabotulinumtoxinA for Post-Stroke Upper Limb Spasticity: Results of a Double-Blind, Placebo-Controlled Trial (P3.027)

Conclusions:Preliminary results from this trial investigating the safety and efficacy of higher-dose onabotA for elbow and shoulder spasticity indicate a dose-related benefit. At the higher total dose of 500U onabotA, no new safety signals were observed; AEs did not appear to be dose-related.Study Supported by: Allergan plcDisclosure: Dr. Patel has received personal compensation for activities with Allergan, Merz, and Ipsen as a speaker and member of scientific advisory boards. Dr. Patel has received research support from Allergan, Merz, Ipsen, and Revance. Dr. Geis has received personal compensation for activities with Allergan as a speaker, consultant, and advisory board member. Dr. Geis has received research support from Allergan. Dr. Alter has nothing to disclose. Dr. Pan has received personal compensation for activities with Allergan as an employee. Dr. Thorpe has received personal compensation for activities with Allergan as an employee. Dr. James has received personal compensation for activities with Allergan and Chase Pharmaceuticals as an employee. Dr. Dimitrova has received personal compensation for activities with Allergan as an employee. Dr. Dimitrova holds stock and/or stock options in Allergan.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Patel, A., Geis, C., Alter, K., Pan, G., Thorpe, A., James, L., Dimitrova, R. Tags: Movement Disorders: Dystonia and Neurotoxin Therapies Source Type: research